About this trial
Background:
Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them understand any changes in cells and genes. These changes might lead to the development and progression of prostate cancer. Researchers think the study could lead to new treatments.
Objective:
To understand the changes in cells and genes that lead to the development and progression of prostate cancer. This could lead to new treatments.
Eligibility:
Men ages 18 and older who have or are suspected to have prostate cancer
Design:
Participants will be screened with physical exam and medical history.
Participants will send tissue blocks of their tumor, if possible. If not, they will provide unstained slides of tumor tissue.
Participants may provide samples of blood, urine, saliva, and prostate secretions.
Participants may have imaging tests. They will lie in a machine that takes pictures of their body. These tests include:
MRI of the prostate
CT of the abdomen and pelvis
Chest x-ray
Participants may need a biopsy or surgery for treatment of their cancer. If so, researchers will collect tissue.
Participants may answer questions about their prostate cancer and quality of life.
Participants may have follow-up visits or other treatments. They may have follow-up phone calls every few months.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults (greater than or equal to 18 years of age) with biopsy-proven or suspected prostate cancer (elevated PSA abnormal digital rectal exam (DRE) abnormal prostate MRI, or family history) who require and are willing to undergo diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or follow-up/surveillance for their neoplasm.
ECOG performance status of 0-2
Must be willing and able to provide informed consent
PSA > or equal to 1.0 ng/ml (for patients aged 30 - 49 years) OR
Disqualifiers
None
Trial population
Adults with biopsy-proven or suspected prostate cancer who require diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or follow-up/surveillance for their neoplasm.
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Collect samples for the purpose of studying the molecular mechanisms of carcinogenesis in prostate cancer
Collection of blood, urine, saliva, expressed prostatic secretions, and benign and malignant tissue
Secondary outcomes
prostate cancer cell lines
Develop stable prostate cancer cell lines from procured tissue when feasible
Natural history of prostate cancer
Collect detailed history, pathologic data, perioperative findings, and treatment data to better characterize the natural and clinical histories of prostate cancer when feasible
Molecular profiling
whole genomic sequence characterizations, identification of specific mutations or single nucleotide polymorphisms (SNPs), comparative genomic hybridization, messenger and microRNA sequencing and expression, RNA Seq, DNA methylation (epigenetics), DNA copy number, and expression profiling
Sponsors and contacts
Click on the lead sponsor to view all of their trials.